Pyridium
Pyridium Price range: $ 55,00 through $ 265,00
Back to products
Ranexa
Ranexa Price range: $ 49,00 through $ 310,00

Quibron-T

Price range: $ 43,00 through $ 492,00

Quibron-T is an effective combination medication designed to manage respiratory conditions such as bronchial asthma, chronic bronchitis, and emphysema. This formula combines theophylline, a powerful bronchodilator, with guaifenesin, a proven expectorant. The theophylline component works by relaxing the smooth muscles of the airways, which helps to keep the bronchial tubes open for easier breathing. Meanwhile, guaifenesin helps to thin and loosen mucus in the chest, making it much easier to clear congestion through productive coughing. Regular use of this medication provides reliable relief from wheezing, shortness of breath, and chest tightness associated with chronic lung diseases.

Active substance: Theophylline
SKU: Quibron-T Categories: ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Quibron-T belongs to a group of medicines called xanthine derivatives, which act as bronchodilators to open airways in the respiratory tract. It is a prescription medication indicated for the symptomatic relief and long-term management of chronic bronchial asthma, chronic bronchitis, and pulmonary emphysema.

Because the active ingredient has a narrow therapeutic range, treatment requires precise dosage adjustments and periodic medical monitoring by a healthcare professional. This drug must be taken strictly in accordance with federal and state regulations under a valid prescription.

Parameter Product Details
Active ingredient Theophylline (anhydrous)
Therapeutic class Xanthine derivatives / Bronchodilators
Dosage form Oral tablet
Route of administration Oral
Prescription status Prescription (Rx) only
Primary purpose Management of reversible airway obstruction in asthma and COPD

How the drug works

The mechanism of action of Quibron-T centers on its active agent, theophylline. Theophylline relaxes the smooth muscle of the bronchial airways and pulmonary blood vessels. It exerts this effect partly by non-selectively inhibiting phosphodiesterase (PDE) enzymes, which leads to an increase in intracellular cyclic adenosine monophosphate (cAMP). Elevated cAMP concentrations decrease smooth muscle contractility and reduce inflammatory mediator release from mast cells and leukocytes. Additionally, theophylline acts as a competitive antagonist at cell-surface adenosine receptors, preventing adenosine-mediated bronchoconstriction. The drug also enhances mucociliary clearance, stimulates the respiratory center in the meudlla, and improves diaphragmatic contractility.

What it’s used for

Quibron-T is indicated for the treatment and prevention of reversible bronchospasm associated with chronic bronchial asthma. It is also prescribed for managing airway obstruction in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. By alleviating smooth muscle constriction, the drug improves pulmonary airflow and decreases respiratory distress symptoms like wheezing and dyspnea. It is intended for maintenance therapy and is not suited for the immediate reversal of acute, severe bronchospasm or status asthmaticus. Any off-label use–such as treatment of neonatal apnea or specific cardiac conduction disorders–must be explicitly evaluated and monitored by a qualified prescriber.

Dosing schedule

Dosage of Quibron-T is individualized based on peak serum theophylline concentrations, clinical response, and patient tolerance. The general therapeutic target range for serum theophylline concentration is 10 to 20 mcg/mL, though levels between 5 and 15 mcg/mL often provide clinical benefit while reducing the potential for adverse effects. Initial dosing begins conservatively and is titrated at 3- to 7-day intervals based on serum level measurements. Tablets are administered orally with liquid. Dose calculations must account for lean body mass, as theophylline distributes minimally into adipose tissue. Specific dose adjustments are mandatory for elderly individuals, pediatric patients, patients with hepatic impairment, and those concurrently taking interfering medications.

How it’s absorbed and eliminated

Following oral administration, the active compound in Quibron-T is rapidly and completely absorbed from the gastrointestinal tract. Peak serum concentrations are generally reached within 1 to 2 hours for immediate-release preparations. Theophylline is extensively metabolized in the liver by hepatic cytochrome P450 enzymes, primarily CYP1A2, into inactive xanthine metabolites including 1,3-dimethyluric acid and 3-methylxanthine. The elimination half-life varies significantly among patient populations: in non-smoking adults, the half-life averages 6 to 12 hours, whereas in cigarette smokers, clearance is accelerated and half-life may decrease to 4 to 5 hours due to enzyme induction. In patients with hepatic cirrhosis or congestive heart failure, the half-life can exceed 24 hours. Excretion of metabolites and unchanged drug occurs through the kidneys.

What not to combine

Quibron-T possesses extensive potential for drug interactions due to its metabolic pathway via hepatic CYP enzymes. Co-administration with potent CYP1A2 inhibitors–such as ciprofloxacin, erythromycin, cimetidine, or fluvoxamine–significantly decreases the clearance of theophylline, leading to elevated blood levels and a heightened risk of toxicity. Conversely, metabolic inducers like rifampin, carbamazepine, phenytoin, and St. John’s wort accelerate drug elimination, potentially diminishing therapeutic efficacy. Concurrent administration of non-selective beta-blockers (e.g., propranolol) can antagonize bronchodilation and provoke severe bronchospasm. Caution is also required when combining the drug with sympathomimetic agents or other xanthines, as additive cardiac and central nervous system stimulation may occur.

Adverse reactions

Adverse reactions associated with Quibron-T are directly related to serum theophylline concentrations. At therapeutic levels, common mild side effects include nausea, vomiting, epigastric pain, headache, insomnia, nervousness, and transient mild diuresis. When serum concentrations exceed 20 mcg/mL, more severe toxic manifestations can emerge without preceding mild symptoms. Toxic reactions include persistent intractable vomiting, sinus tachycardia, atrial or ventricular arrhythmias, hypotension, hypokalemia, hyperglycemia, and generalized tonic-clonic seizures. Patients who experience severe gastrointestinal distress or irregular heart rhythms require immediate clinical assessment and serum concentration testing.

Important precautions

Caution must be exercised when prescribing Quibron-T to individuals with peptic ulcer disease, active cardiac arrhythmias, severe heart disease, hyperthyroidism, hypertension, or underlying seizure disorders, as the drug can exacerbate these clinical conditions. Dosage adjustments and careful therapeutic drug monitoring are required in special populations, particularly elderly patients and those with hepatic impairment or severe heart failure. Pregnancy requires careful risk-benefit analysis; theophylline crosses the placental barrier and is excreted into breast milk. Acute febrile illnesses can decrease clearance, necessitating a temporary dosage reduction during prolonged high fever.

What to avoid while taking it

Dietary habits can affect the pharmacokinetic profile of Quibron-T. Consuming high-fat meals prior to ingestion may alter the rate of drug absorption. Excessive intake of caffeine-containing foods and beverages (such as coffee, tea, and energy drinks) should be avoided, as caffeine is a xanthine derivative that can potentiate central nervous system and cardiovascular stimulation. Alcohol consumption should be restricted because ethanol can impair liver metabolism, leading to elevated serum concentrations. High-protein or high-carbohydrate diets can also alter clearance rates and should be kept consistent during therapy.

If you skip a dose

If a dose of Quibron-T is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule resumed. Patients must never double a dose or take extra tablets to compensate for a missed administration, as elevated peak concentrations increase the risk of severe toxicity.

Red flags

Immediate emergency medical assistance is necessary if symptoms of severe toxicity or hypersensitivity occur. A patient presenting symptoms in an emergency care setting in Houston or Chicago should seek urgent evaluation if any of the following signs appear:

  • Persistent, intractable nausea or vomiting
  • Rapid, irregular, or pounding heartbeat (cardiac arrhythmias)
  • Seizures or severe muscle tremors
  • Confusion, extreme agitation, or dizziness
  • Severe hypersensitivity reactions, including swelling of the face, tongue, or throat, or acute respiratory distress

Storage and expiration

Quibron-T should be stored at controlled room temperature between 68°F and 77°F (20°C to 25°C). The container must be kept tightly closed and protected from exposure to excessive heat, light, and moisture. Store the medication away from humid environments such as bathrooms. Keep all pharmaceuticals out of the reach of children and pets. Do not use the medication past the expiration date printed on the original container. Unused or expired medication should be disposed of via local pharmacy collection programs.

Common questions

How often is blood testing required while taking Quibron-T?

Blood testing to measure serum concentrations is typically performed when starting treatment, after dose adjustments, or if signs of toxicity or therapeutic failure appear. Once a stable therapeutic level is established within the target range (10 to 20 mcg/mL), routine monitoring is conducted periodically or when adding interacting medications.

Can smoking cigarettes alter the effectiveness of this medication?

Yes. Tobacco smoke induces the CYP1A2 liver enzymes responsible for metabolizing the active ingredient. As a result, smokers eliminate the drug much faster than non-smokers and often require higher daily doses. Conversely, quitting smoking while on therapy can decrease clearance and lead to elevated blood concentrations if the dose is not adjusted.

What should be done if mild nausea occurs after taking a dose?

Mild gastrointestinal distress can sometimes occur early in treatment. Taking the medication with meals or a full glass of water may help reduce stomach upset. However, if nausea is persistent, severe, or accompanied by vomiting, it may indicate elevated blood levels and requires immediate medical evaluation.

Are over-the-counter cold remedies safe to use concurrently?

Many over-the-counter cold and cough preparations contain decongestants (such as pseudoephedrine) or stimulants that can interact with Quibron-T. Combining these products can increase the risk of rapid heart rate, nervousness, and elevated blood pressure. Patients should consult a doctor or pharmacist before taking OTC remedies.

Can therapy be stopped abruptly if respiratory symptoms improve?

Treatment should not be discontinued without consulting the prescribing healthcare provider. Abrupt cessation of bronchodilator therapy can lead to a recurrence or worsening of airway constriction in asthma or COPD. Dosage adjustments or discontinuation must be managed under medical supervision.

In accordance with FDA requirements.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

200 mg

,

400mg

Package

30 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία